LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Начало・Списък с акции・Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

44.57 0.34

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

44.48

Максимум

44.97

Ключови измерители
By Trading Economics
Приходи	36M -2.3M
Продажби	-3.9M 208M
P/E Средно за сектора	48.435 49.888
EPS	0.21
Марж на печалбата	-1.104
Служители	778
EBITDA	-72M 19M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+40.22% upside

Дивиденти
By Dow Jones
Следващи печалби	4.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-202M 2.6B
Предишно отваряне	44.23
Предишно затваряне	44.57

Настроения в новините

By Acuity

14%

86%

11 / 344 Класиране в Healthcare

Supernus Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.06.2026 г., 19:20 ч. UTC

Значими двигатели на пазара

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

6.06.2026 г., 08:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

6.06.2026 г., 04:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.06.2026 г., 00:14 ч. UTC

Придобивния, сливания и поглъщания

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5.06.2026 г., 21:27 ч. UTC

Печалби

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5.06.2026 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5.06.2026 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.06.2026 г., 19:26 ч. UTC

Пазарно говорене

Hog Futures Tumble to Close Week -- Market Talk

5.06.2026 г., 19:10 ч. UTC

Пазарно говорене

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5.06.2026 г., 19:03 ч. UTC

Пазарно говорене

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5.06.2026 г., 18:59 ч. UTC

Пазарно говорене

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5.06.2026 г., 18:47 ч. UTC

Пазарно говорене

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5.06.2026 г., 18:34 ч. UTC

Пазарно говорене

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5.06.2026 г., 18:33 ч. UTC

Придобивния, сливания и поглъщания

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5.06.2026 г., 17:50 ч. UTC

Печалби

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5.06.2026 г., 17:27 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5.06.2026 г., 16:48 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

5.06.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

5.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

5.06.2026 г., 15:44 ч. UTC

Придобивния, сливания и поглъщания

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5.06.2026 г., 15:26 ч. UTC

Пазарно говорене

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5.06.2026 г., 15:25 ч. UTC

Печалби

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5.06.2026 г., 15:16 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Supernus Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

40.22% нагоре

12-месечна прогноза

Среден 62.75 USD 40.22%

Висок 66 USD

Нисък 55 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за Supernus Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на Supernus Pharmaceuticals Inc през последните 3 месеца.

Настроение

By Acuity

11 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.